Table 2.
Parametera | Viral loadb | CD4+ T cell countb | ||
---|---|---|---|---|
ρ | P | ρ | P | |
%CD3+pSTAT5+ | ||||
Constitutive (n = 118) | 0.23 | .011 | −0.22 | .014 |
IL-2 induced (n = 118) | −0.24 | .007 | −0.05 | .544 |
IL-7 induced (n = 118) | −0.62 | <.001 | 0.46 | <.001 |
IL-15 induced (n = 110) | −0.18 | .049 | −0.09 | .324 |
Receptor | ||||
CD25 (n = 97) | −0.23 | .021 | 0.16 | .10 |
CD122 (n = 104) | 0.23 | .019 | −0.18 | .055 |
CD132 (n = 104) | 0.32 | .001 | −0.19 | .044 |
CD127 (n = 104) | −0.50 | <.001 | 0.38 | <.001 |
NOTE. Data show Spearman correlations (ρ and P values) between the levels of constitutive and cytokine-induced pSTAT5 and the viral load and CD4+ T cell counts. These analyses include all subjects, regardless of the treatment status. %CD3+pSTAT5+, percentage of CD3+ cells that express pSTAT5; ρ, Spearman’s rank correlation coefficient.
The number of subjects from whom the data were derived is shown in parentheses.
Mean CD4+ T cell counts and viral load measurements in the 1 year before the date of assessment of the parameters listed in this table.